Drug
Bevacizumab
Data on this page refer exclusively to patients treated with
Bevacizumab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
VEGF mAb group page.
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Anti-VEGF |
| Group | VEGF mAb |
| Mechanism of Action | Anti-VEGF antibody |
| Half-life | 18-20 d |
Location
Treated site
